Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 1/20 | 0.50 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.47 |
| ▸ | HRH1 | P35367 | 2/20 | 0.45 |
| ▸ | TLR8 | Q9NR97 | 2/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7501008 | 0.84 | ALDH1A1 (0.51) | CHRNA7CYP2A6CYP1A2CYP2D6L3MBTL1 | |
| SCHEMBL8543898 | 0.83 | TLR8 (0.50) | TLR8CYP1A2CYP2D6L3MBTL1 | |
| SCHEMBL6636184 | 0.82 | TLR8 (0.49) | TLR8 | |
| SCHEMBL17974587 | 0.81 | CHRNA7 (0.46) | CHRNA7CYP2A6HRH1CYP1A2CYP2D6 | |
| SCHEMBL6638993 | 0.80 | TLR8 (0.50) | HRH1TLR8CYP1A2HRH3TDP1 | |
| SCHEMBL6640843 | 0.80 | TLR8 (0.47) | HRH1TLR8L3MBTL1 | |
| SCHEMBL6642392 | 0.79 | TLR8 (0.46) | TLR8 | |
| SCHEMBL6639142 | 0.77 | LMNA (0.52) | CHRNA7TLR8L3MBTL1 | |
| SCHEMBL6636963 | 0.76 | TLR8 (0.43) | TLR8 | |
| SCHEMBL6640697 | 0.76 | TLR8 (0.46) | TLR8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1185521-B1 | SUBSTITUTED 1-AZA-2-IMINO-HETEROCYCLES AND THEIR USE AS ACTIVATORS OF NICOTINIC ACETYLCHOLINE RECEPTORS | DAIICHI SUNTORY PHARMA CO LTD (JP) | 2004-10-06 | — | — | EP | claimed |
| US-20030134848-A1 | Substituted 1-aza-2-imino-heterocycles and their use as nicotinic acetylcholin receptors activators | DAIICHI SUNTORY PHARMA CO., LTD. (JP) | 2003-07-17 | — | — | US | claimed |
| CN-1366521-A | Substituted 1-aza-2-imino heterocycles and their use as nicotinic acetylcholine receptors activators | SUNTORY LTD (JP) | 2002-08-28 | — | — | CN | claimed |
| EP-1185521-A1 | SUBSTITUTED 1-AZA-2-IMINO-HETEROCYCLES AND THEIR USE AS ACTIVATORS OF NICOTINIC ACETYLCHOLINE RECEPTORS | SUNTORY LIMITED (JP) | 2002-03-13 | — | — | EP | claimed |
| WO-2001081326-A1 | SUBSTITUTED 1-AZA-2-IMINO-HETEROCYCLES AND THEIR USE AS NICOTINIC ACETYLCHOLINE RECEPTORS ACTIVATORS | SUNTORY LIMITED (JP) | 2001-11-01 | — | — | WO | claimed |
| EP-1185521-B1 | SUBSTITUTED 1-AZA-2-IMINO-HETEROCYCLES AND THEIR USE AS ACTIVATORS OF NICOTINIC ACETYLCHOLINE RECEPTORS | DAIICHI SUNTORY PHARMA CO LTD (JP) | 2004-10-06 | — | — | EP | disclosed |
| US-20030134848-A1 | Substituted 1-aza-2-imino-heterocycles and their use as nicotinic acetylcholin receptors activators | DAIICHI SUNTORY PHARMA CO., LTD. (JP) | 2003-07-17 | — | — | US | disclosed |
| CN-1366521-A | Substituted 1-aza-2-imino heterocycles and their use as nicotinic acetylcholine receptors activators | SUNTORY LTD (JP) | 2002-08-28 | — | — | CN | disclosed |
| EP-1185521-A1 | SUBSTITUTED 1-AZA-2-IMINO-HETEROCYCLES AND THEIR USE AS ACTIVATORS OF NICOTINIC ACETYLCHOLINE RECEPTORS | SUNTORY LIMITED (JP) | 2002-03-13 | — | — | EP | disclosed |
| WO-2001081326-A1 | SUBSTITUTED 1-AZA-2-IMINO-HETEROCYCLES AND THEIR USE AS NICOTINIC ACETYLCHOLINE RECEPTORS ACTIVATORS | SUNTORY LIMITED (JP) | 2001-11-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030134848-A1 | Substituted 1-aza-2-imino-heterocycles and their use as nicotinic acetylcholin receptors activators | CHRNA7, CHRNA2, CHRNA1 | CHRNA7 1/4885CYP2A6 311/4885HRH1 1274/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.